BMY240802C48000
- 0.96
- -0.54-36.00%
Bristol-Myers Squibb Newsroom
Pfizer Exec Says Shares Bristol Myers' View That Co Has The Ability To Navigate The Impact Of IRA On Eliquis; Eliquis Will Be An Important Drug In Co's Portfolio For The Foreseeable Future, From A Net Present Value Perspective, The Impact Of Ira On...
Express News | Pfizer Exec Says $1.5 Billion of Cost Savings Is Only From Phase One of a Multiple Phase Program
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
Express News | Pfizer Exec Says From a Net Present Value Perspective, the Impact of Ira on Pfizer Is Somewhat Muted
Express News | Pfizer Exec Says Eliquis Will Be an Important Drug in Co's Portfolio for the Foreseeable Future
Express News | Pfizer Exec Says Shares Bristol Myers' View That Co Has the Ability to Navigate the Impact of Ira on Eliquis
Express News | Bristol-Myers Squibb Co : UBS Raises Target Price to $50 From $43
A Quick Look at Today's Ratings for Bristol-Myers Squibb(BMY.US), With a Forecast Between $37 to $62
Express News | Bristol-Myers Squibb Company : Barclays Cuts to Underweight From Equal-Weight
Pfizer Stock Gains After Raising Annual Outlook
Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns
USA pharmaceutical stocks 'switching trading': two weight-loss giants fall, while stagnant giants rise in turn.
The rotation of this stock price is not only due to momentum effects, but also because the USA pharmaceutical industry seems to have responded well to the regulatory pressure brought by the Inflation Reduction Act.
Bristol-Myers Squibb Options Spot-On: On July 29th, 84,323 Contracts Were Traded, With 861.54K Open Interest
Barclays Cuts Bristol Myers to Underweight, Cites Recent Run up
Bristol-Myers Stock Snaps Six Days of Gains
Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings
Bristol-Myers Squibb on Track for Longest Winning Streak Since April 2021 -- Data Talk
Wolfe Adjusts Price Target on Bristol-Myers Squibb to $57 From $55, Maintains Outperform Rating
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields
This Bristol-Myers Squibb Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday